Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 226-002-3 | CAS number: 5205-93-6
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
Based on the results of three reliable in vitro studies (Ames test according to OECD 471, HPRT test according to OECD 476 and Chromosome
aberration assay according to OECD 473), N-[3 -(dimethylamino)propyl)methacrylamide shows no potential to induce gene mutations in bacterial
cells nor does it induce chromosomal aberrations. Therefore, it is concluded that DMAPMA is unlikely to be mutagenic in vivo. This conclusion was supported by an in vivo B6C3F1 mouse bone marrow micronucleus assay (standard NTP protocol) where DMAPMA was not mutagenic.
- not mutagenic in the Salmonella typhimurium reverse mutation assay (OECD guideline 471; GLP, RCC Cytotest Cell Research GmbH, 1994)
- not mutagenic in the mammalian cell gene mutation assay (OECD guideline 476; HPRT test, V79 cells; GLP, CCR Cytotest Cell Research GmbH, 1994)
- negative in an in vitro Chromosome aberration assay in Chinese V79 cells (OECD guideline 473; GLP, CCR Cytotest Cell Research GmbH, 1994)
There is one in vivo genetic toxicity study identified for N-[3 -(dimethylamino)propyl)methacrylamide. In this B6C3F1 mouse bone marrow micronucleus assay (standard NTP protocol) N-[3 -(dimethylamino)propyl)methacrylamide was also negative.
No single key study has been selected, since all available studies were negative.
There is no evidence for mutagenicity from in vitro and in vivo studies.
The data requirements with regard to REACH legislation, annex VII – X, are fulfilled.
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
Based on the results of in vitro and in vivo studies N-[3-(dimethylamino)propyl)methacrylamide is not required to be classified for mutagenicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
